Ibex Investors LLC Alaunos Therapeutics, Inc. Transaction History

Ibex Investors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$1.9 - $4.98 $67,809 - $177,731	-35,689 Closed	0 $0
Q4 2019 Feb 05, 2020	SELL	$3.95 - $5.35 $140,971 - $190,936	-35,689 Reduced 50.0%	35,689 $168,000
Q4 2019 Feb 05, 2020	BUY	$3.95 - $5.35 $111,291 - $150,736	28,175 Added 65.22%	71,378 $336,000
Q3 2019 Nov 01, 2019	SELL	$4.13 - $6.94 $365,971 - $614,974	-88,613 Reduced 67.22%	43,203 $185,000
Q2 2019 Jul 29, 2019	SELL	$3.98 - $6.2 $212,814 - $331,520	-53,471 Reduced 28.86%	131,816 $768,000
Q1 2019 May 07, 2019	SELL	$2.0 - $4.4 $436,726 - $960,797	-218,363 Reduced 54.1%	185,287 $713,000
Q4 2018 Feb 13, 2019	BUY	$1.61 - $3.62 $649,876 - $1.46 Million	403,650 New	403,650 $755,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Ibex Investors LLC, based on Form 13F filings with the SEC.

Stay updated on Ibex Investors LLC with notifications on news.